Pakistan · Delayed Price · Currency is PKR Citi Pharma Statistics
Total Valuation
Citi Pharma has a market cap or net worth of PKR 17.80 billion. The enterprise value is 20.35 billion.
| Market Cap | 17.80B |
| Enterprise Value | 20.35B |
Important Dates
The last earnings date was Friday, February 13, 2026.
| Earnings Date | Feb 13, 2026 |
| Ex-Dividend Date | Oct 17, 2025 |
Share Statistics
Citi Pharma has 228.46 million shares outstanding. The number of shares has increased by 0.13% in one year.
| Current Share Class | 228.46M |
| Shares Outstanding | 228.46M |
| Shares Change (YoY) | +0.13% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | 38.66% |
| Owned by Institutions (%) | 14.65% |
| Float | 135.64M |
Valuation Ratios
The trailing PE ratio is 17.13 and the forward PE ratio is 18.55.
| PE Ratio | 17.13 |
| Forward PE | 18.55 |
| PS Ratio | 1.26 |
| PB Ratio | 1.67 |
| P/TBV Ratio | 1.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.94, with an EV/FCF ratio of -19.83.
| EV / Earnings | 19.54 |
| EV / Sales | 1.44 |
| EV / EBITDA | 8.94 |
| EV / EBIT | 9.82 |
| EV / FCF | -19.83 |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of 0.53.
| Current Ratio | 1.21 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.53 |
| Debt / EBITDA | 2.49 |
| Debt / FCF | -5.52 |
| Interest Coverage | 4.68 |
Financial Efficiency
Return on equity (ROE) is 13.00% and return on invested capital (ROIC) is 10.01%.
| Return on Equity (ROE) | 13.00% |
| Return on Assets (ROA) | 7.75% |
| Return on Invested Capital (ROIC) | 10.01% |
| Return on Capital Employed (ROCE) | 18.85% |
| Weighted Average Cost of Capital (WACC) | 6.16% |
| Revenue Per Employee | 26.55M |
| Profits Per Employee | 1.96M |
| Employee Count | 531 |
| Asset Turnover | 0.84 |
| Inventory Turnover | 3.01 |
Taxes
In the past 12 months, Citi Pharma has paid 604.42 million in taxes.
| Income Tax | 604.42M |
| Effective Tax Rate | 36.72% |
Stock Price Statistics
The stock price has decreased by -12.17% in the last 52 weeks. The beta is 0.42, so Citi Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -12.17% |
| 50-Day Moving Average | 85.85 |
| 200-Day Moving Average | 87.65 |
| Relative Strength Index (RSI) | 39.74 |
| Average Volume (20 Days) | 2,315,773 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Citi Pharma had revenue of PKR 14.10 billion and earned 1.04 billion in profits. Earnings per share was 4.55.
| Revenue | 14.10B |
| Gross Profit | 2.53B |
| Operating Income | 2.07B |
| Pretax Income | 1.65B |
| Net Income | 1.04B |
| EBITDA | 2.26B |
| EBIT | 2.07B |
| Earnings Per Share (EPS) | 4.55 |
Balance Sheet
The company has 3.12 billion in cash and 5.67 billion in debt, with a net cash position of -2.55 billion or -11.16 per share.
| Cash & Cash Equivalents | 3.12B |
| Total Debt | 5.67B |
| Net Cash | -2.55B |
| Net Cash Per Share | -11.16 |
| Equity (Book Value) | 10.68B |
| Book Value Per Share | 46.73 |
| Working Capital | 2.04B |
Cash Flow
In the last 12 months, operating cash flow was -943.91 million and capital expenditures -82.81 million, giving a free cash flow of -1.03 billion.
| Operating Cash Flow | -943.91M |
| Capital Expenditures | -82.81M |
| Free Cash Flow | -1.03B |
| FCF Per Share | -4.49 |
Margins
Gross margin is 17.92%, with operating and profit margins of 14.70% and 7.39%.
| Gross Margin | 17.92% |
| Operating Margin | 14.70% |
| Pretax Margin | 11.68% |
| Profit Margin | 7.39% |
| EBITDA Margin | 16.00% |
| EBIT Margin | 14.70% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 4.42%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 4.42% |
| Dividend Growth (YoY) | 7.69% |
| Years of Dividend Growth | 4 |
| Payout Ratio | 76.48% |
| Buyback Yield | -0.13% |
| Shareholder Yield | 4.30% |
| Earnings Yield | 5.85% |
| FCF Yield | -5.77% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on October 18, 2021. It was a forward split with a ratio of 1.1.
| Last Split Date | Oct 18, 2021 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
Citi Pharma has an Altman Z-Score of 2.41 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.41 |
| Piotroski F-Score | 3 |